Publications

Publications

Filter Results: (309) Arrow Down

Show Results For

← Page 4 of 309 Results →
  • June 2024
  • Article

Valuing the Societal Impact of Medicines and Other Health Technologies: A User Guide to Current Best Practices

By: Jason Shafrin, Jaehong Kim, Joshua T. Cohen, Louis P. Garrison, Dana A. Goldman, Jalpa A. Doshi, Joshua Krieger, Darius N. Lakdawalla, Peter J. Neumann, Charles E. Phelps, Melanie D. Whittington and Richard Willke
This study argues that value assessment conducted from a societal perspective should rely on the Generalized Cost-Effectiveness Analysis (GCEA) framework proposed herein. Recently developed value assessment inventories—such as the Second Panel on Cost-Effectiveness’s... View Details
Keywords: Health Care and Treatment; Valuation; Cost vs Benefits; Society
Related
  • 2023
  • Article

Dynamic HTA for Digital Health Solutions: Opportunities and Challenges for Patient-Centered Evaluation

By: Jan B. Brönneke, Annika Herr, Simon Reif and Ariel D. Stern
Germany’s 2019 Digital Healthcare Act (Digitale-Versorgung-Gesetz, or DVG) created a number of opportunities for the digital transformation of the health care delivery system. Key among these was the creation of a reimbursement pathway for patient-centered digital... View Details
Keywords: Digital Transformation; Applications and Software; Product Development; Insurance; Policy; Health Industry; Germany
Related
  • March 2008
  • Case

Novartis AG: Science-Based Business

By: H. Kent Bowen and Courtney Purrington
Novartis is a science-based drug company, which has important implications for its business strategy. It is one of the largest pharmaceutical companies in the world with over $38B in sales in 2007. Pharmaceuticals account for slightly over $24B of that total. In 2007,... View Details
Keywords: Innovation and Invention; Resource Allocation; Product Development; Partners and Partnerships; Research and Development; Science-Based Business; Pharmaceutical Industry
Related
  • 15 Jan 2019
  • First Look

New Research and Ideas, January 15, 2019

December 19, 2018 NEJM Catalyst It's Time to Reform the Orphan Drug Act By: Bagley, Nicholas, Amitabh Chandra, Craig Garthwaite, and Ariel Dora Stern Abstract—No abstract available. Publisher's link:... View Details
Keywords: Dina Gerdeman
  • Web

Faculty & Advisors | MBA

M.D. MS/MBA Program Faculty Co-Chair for MS Professor of Stem Cell and Regenerative Biology at Harvard University, Chief of Pathways Consult Service at Massachusetts General Hospital Douglas Melton, Ph.D. MS/MBA Program Faculty Co-Chair... View Details
  • 11 Oct 2006
  • Research & Ideas

The Success of Reverse Leveraged Buyouts

business press and savvy business experts such Warren Buffett. It didn’t help when one of the most publicized RLBOs—Refco—collapsed in 2005 shortly after its initial public offering. And on September 21, a 70-million share offering for View Details
Keywords: by Sean Silverthorne; Banking; Financial Services
  • 14 Nov 2017
  • First Look

New Research and Ideas: November 14, 2017

authors provide numerous examples of health care organizations that are taking these steps—and seeing impressive results. Publisher's link: https://www.hbs.edu/faculty/Pages/item.aspx?num=53460 forthcoming JAMA Cardiology The Central and Unacknowledged Role of the U.S.... View Details
Keywords: Carmen Nobel
  • 21 Aug 2007
  • First Look

First Look: August 21, 2007

http://www.hbsp.harvard.edu/b01/en/common/item_detail.jhtml?id=807074   PublicationsPerspectives on Risk and Regulation: The FDA at 100 Author:Arthur A. Daemmrich Publication:Chemical Heritage Press, 2007 Abstract Perspectives on Risk and Regulation: The FDA at 100... View Details
Keywords: Martha Lagace
  • 05 Sep 2023
  • Book

Failing Well: How Your ‘Intelligent Failure’ Unlocks Your Full Potential

In the 1990s, after drugmaker Eli Lilly spent more than a decade and millions of dollars developing the new drug Alimta to treat lung cancer, the medication came up short in effectively treating cancer in expanded trials. While the... View Details
Keywords: by Michael Blanding
  • Research Summary

Overview

By: Joshua Lev Krieger
In examining the competitive dynamics of R&D strategy, Josh has become particularly interested in how the introduction of new knowledge generated by rivals impacts the direction of R&D efforts. Understanding how new information alters project portfolio decisions is... View Details
  • Web

Great American Business Leaders of the 20th Century - Leadership

Telephone and Telegraph, 1997–2002 Desiderio A. Arnaz Desilu Productions, 1950–1962 Mary Kay Ash Mary Kay Cosmetics, 1963–1987 Roy L. Ash Litton Industries, 1961–1972 H. Brewster Atwater, Jr. General Mills, 1981–1995 Beatrice F. Auerbach... View Details
  • Web

Blavatnik Fellowship in Life Science Entrepreneurship - Health Care

KiraGen Bio to create substantial value for all stakeholders. Stephen Linderman MD, PhD 2019 Stephen Linderman is the CEO and co-founder of Absco Therapeutics (AbscoTx), an immune oncology company specializing in image-guided, intratumoral View Details
  • 23 Sep 2008
  • First Look

First Look: September 23, 2008

claims, and an infusion of new equity financing. The Chapter 11 process has generated both costs and benefits for the company. Its future profitability, and the value of the reorganized business, are both highly uncertain. Purchase the... View Details
Keywords: Martha Lagace
  • Web

Degrees, Certifications & Alumni Status | About

locations, or onsite with an organization. Harvard Business School grants alumni status with successful completion of any of the following programs: the Advanced Management Program, General Management Program, Owner/President Management,... View Details
  • 10 Oct 2007
  • First Look

First Look: First Look: October 10

broad-based therapies. Instead, the focus should be on enrolling subpopulations, based on diagnostic testing, in trials of targeted drug treatments and on monitoring and assessing effectiveness after drugs... View Details
Keywords: Martha Lagace
  • Web

Curriculum - Case Method Project

decision; Abolitionists; rise of the Republican Party; Lincoln/Douglas Debates; tariffs; Election of 1860; Southern Secession; Fort Sumter Reconstruction A: The Crisis of 1877 This case provides a general overview of Reconstruction,... View Details
  • 30 Apr 2024
  • Book

When Managers Set Unrealistic Expectations, Employees Cut Ethical Corners

willing to approve continued sales of a drug known to be lethal to some customers in fulfilment of their assigned role to maximise value for shareholders (Armstrong, 1977, p. 204). And so on. Yet, the insights from this research and their... View Details
Keywords: by Dina Gerdeman
  • 05 Dec 2017
  • First Look

First Look at New Research and Ideas, December 5, 2017

S. Fader, Sunil Gupta, Bruce Hardie, Aurelie Lemmens, Barak Libai, David T. Neal, Foster Provost, and Rom Schrift Abstract—In today’s turbulent business environment, customer retention presents a significant challenge for many service companies. Academics have View Details
Keywords: Sean Silverthorne
  • 25 Jul 2023
  • Research & Ideas

Could a Business Model Help Big Pharma Save Lives and Profit?

With Hepatitis C running rampant in Egypt in 2012, Clifford Samuel, then of California-based Gilead Sciences, convened a series of urgent meetings with Egyptian government officials, doctors, and patients. His goal? To make Gilead’s lifesaving Hepatitis C View Details
Keywords: by Esther Schrader; Pharmaceutical; Health
  • 01 Dec 2023
  • News

Wide Horizon

two bigger players begin to invest in the drug for ASD. He wasn’t frustrated by the competition; he was relieved. Getting new ideas to market is a positive outcome, no matter who takes it there. “I want to focus on View Details
Keywords: Dan Morrell; Photos by Sarah Wilson